Amber Balazs

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

James S. Scott, Amber Balazs, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2020 · 111 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structural and Physicochemical Features of Oral PROTACs

Markus Schade, James S. Scott, Thomas G. Hayhow et al. · Journal of Medicinal Chemistry · 2024 · 57 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles

Amber Balazs, Rodrigo J. Carbajo, Nichola L. Davies et al. · Journal of Medicinal Chemistry · 2019 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2024 · 27 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13